Janet L. Oblinger

695 total citations
21 papers, 456 citations indexed

About

Janet L. Oblinger is a scholar working on Molecular Biology, Neurology and Epidemiology. According to data from OpenAlex, Janet L. Oblinger has authored 21 papers receiving a total of 456 indexed citations (citations by other indexed papers that have themselves been cited), including 12 papers in Molecular Biology, 11 papers in Neurology and 6 papers in Epidemiology. Recurrent topics in Janet L. Oblinger's work include Neurofibromatosis and Schwannoma Cases (11 papers), Meningioma and schwannoma management (6 papers) and Glycosylation and Glycoproteins Research (3 papers). Janet L. Oblinger is often cited by papers focused on Neurofibromatosis and Schwannoma Cases (11 papers), Meningioma and schwannoma management (6 papers) and Glycosylation and Glycoproteins Research (3 papers). Janet L. Oblinger collaborates with scholars based in United States, Canada and Malaysia. Janet L. Oblinger's co-authors include Long‐Sheng Chang, D. Bradley Welling, Sarah S. Burns, Matthew L. Bush, Abraham Jacob, A. J. Yates, Elena M. Akhmametyeva, Jie Huang, A. Douglas Kinghorn and Yulin Ren and has published in prestigious journals such as Cancer Research, Scientific Reports and Journal of Neurochemistry.

In The Last Decade

Janet L. Oblinger

20 papers receiving 450 citations

Peers

Janet L. Oblinger

NEURO

EPIDE

ONCOL

Concepción Fiaño Spain

Fenghua Zhou China

Anice Moumen France

I‐Li Tan United States

Clare F. Malone United States

Norichika Hashimoto Japan

Ivana Huvar United States

Barbara Witek Sweden

Luo-an Fu China

D Housman United States

Concepción Fiaño Spain

Janet L. Oblinger

252 ×1.0

96 ×0.6

NEURO

94 ×0.8

EPIDE

131 ×1.7

55 ×1.0

ONCOL

Citations per year, relative to Janet L. Oblinger Janet L. Oblinger (= 1×) peers Concepción Fiaño

Countries citing papers authored by Janet L. Oblinger

Since Specialization

Citations

This map shows the geographic impact of Janet L. Oblinger's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Janet L. Oblinger with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Janet L. Oblinger more than expected).

Fields of papers citing papers by Janet L. Oblinger

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Janet L. Oblinger. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Janet L. Oblinger. The network helps show where Janet L. Oblinger may publish in the future.

Co-authorship network of co-authors of Janet L. Oblinger

This figure shows the co-authorship network connecting the top 25 collaborators of Janet L. Oblinger. A scholar is included among the top collaborators of Janet L. Oblinger based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Janet L. Oblinger. Janet L. Oblinger is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Oblinger, Janet L., Roberta L. Beauchamp, Françis Robert, et al.. (2024). Preclinical evaluation of the third-generation, bi-steric mechanistic target of rapamycin complex 1-selective inhibitor RMC-6272 in NF2-deficient models. Neuro-Oncology Advances. 6(1). vdae024–vdae024.

Oblinger, Janet L., Garima Agarwal, Joelle M. Fenger, et al.. (2024). Anti-tumor effects of the eIF4A inhibitor didesmethylrocaglamide and its derivatives in human and canine osteosarcomas. Scientific Reports. 14(1). 19349–19349. 1 indexed citations

Oblinger, Janet L., Roberta L. Beauchamp, Serkan Erdin, et al.. (2023). Proteasomal pathway inhibition as a potential therapy for NF2-associated meningioma and schwannoma. Neuro-Oncology. 25(9). 1617–1630. 4 indexed citations

Welling, D. Bradley, Katharine A. Collier, Sarah S. Burns, et al.. (2021). Early phase clinical studies of AR‐42, a histone deacetylase inhibitor, for neurofibromatosis type 2‐associated vestibular schwannomas and meningiomas. Laryngoscope Investigative Otolaryngology. 6(5). 1008–1019. 24 indexed citations

Oblinger, Janet L., et al.. (2021). Neurofibromatosis: Molecular Pathogenesis and Natural Compounds as Potential Treatments. Frontiers in Oncology. 11. 698192–698192. 7 indexed citations

Chang, Long‐Sheng, Janet L. Oblinger, Sarah S. Burns, et al.. (2019). Targeting Protein Translation by Rocaglamide and Didesmethylrocaglamide to Treat MPNST and Other Sarcomas. Molecular Cancer Therapeutics. 19(3). 731–741. 16 indexed citations

Oblinger, Janet L., Sarah S. Burns, Jie Huang, et al.. (2017). Overexpression of eIF4F components in meningiomas and suppression of meningioma cell growth by inhibiting translation initiation. Experimental Neurology. 299(Pt B). 299–307. 23 indexed citations

Oblinger, Janet L., Sarah S. Burns, Elena M. Akhmametyeva, et al.. (2016). Components of the eIF4F complex are potential therapeutic targets for malignant peripheral nerve sheath tumors and vestibular schwannomas. Neuro-Oncology. 18(9). 1265–1277. 27 indexed citations

Spear, Samuel A., Sarah S. Burns, Janet L. Oblinger, et al.. (2013). Natural Compounds as Potential Treatments of NF2-Deficient Schwannoma and Meningioma. Otology & Neurotology. 34(8). 1519–1527. 23 indexed citations

10.

Burns, Sarah S., Elena M. Akhmametyeva, Janet L. Oblinger, et al.. (2012). Histone Deacetylase Inhibitor AR-42 Differentially Affects Cell-cycle Transit in Meningeal and Meningioma Cells, Potently Inhibiting NF2 -Deficient Meningioma Growth. Cancer Research. 73(2). 792–803. 38 indexed citations

11.

Bush, Matthew L., Sarah S. Burns, Janet L. Oblinger, et al.. (2012). Treatment of Vestibular Schwannoma Cells With ErbB Inhibitors. Otology & Neurotology. 33(2). 244–257. 14 indexed citations

12.

Bush, Matthew L., Janet L. Oblinger, Jie Huang, et al.. (2011). AR42, a novel histone deacetylase inhibitor, as a potential therapy for vestibular schwannomas and meningiomas. Neuro-Oncology. 13(9). 983–999. 64 indexed citations

13.

Jacob, Abraham, Janet L. Oblinger, Matthew L. Bush, et al.. (2011). Preclinical validation of AR42, a novel histone deacetylase inhibitor, as treatment for vestibular schwannomas. The Laryngoscope. 122(1). 174–189. 32 indexed citations

14.

Chai, Guolin, Ning Liu, Junrong Ma, et al.. (2010). MicroRNA‐10b regulates tumorigenesis in neurofibromatosis type 1. Cancer Science. 101(9). 1997–2004. 82 indexed citations

15.

Sahenk, Zarife, et al.. (2008). Neurotrophin-3 deficient Schwann cells impair nerve regeneration. Experimental Neurology. 212(2). 552–556. 26 indexed citations

16.

Oblinger, Janet L., Dennis K. Pearl, Thomas W. Prior, et al.. (2006). Diagnostic and prognostic value of glycosyltransferase mRNA in glioblastoma multiforme patients. Neuropathology and Applied Neurobiology. 32(4). 410–418. 17 indexed citations

17.

Dasgupta, Somsankar, et al.. (2006). Endogenous GD3 ganglioside induces apoptosis in U‐1242 MG glioma cells. Journal of Neurochemistry. 96(5). 1301–1314. 21 indexed citations

18.

Oblinger, Janet L., et al.. (2006). TRAIL-Induced Apoptosis in U-1242 MG Glioma Cells. Journal of Neuropathology & Experimental Neurology. 65(2). 152–161. 8 indexed citations

19.

Oblinger, Janet L., et al.. (2003). Domain-Dependent Modulation of PDGFRβ by Ganglioside GM1. Journal of Molecular Neuroscience. 20(2). 103–114. 10 indexed citations

20.

Rampersaud, Arfaan, Janet L. Oblinger, Ravi K. Ponnappan, Richard W. Burry, & A. J. Yates. (1999). Gangliosides and growth factor receptor regulation. Biochemical Society Transactions. 27(4). 415–422. 18 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact